[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biogen Inc (BIIB)

Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 28,606,142
  • Shares Outstanding, K 147,637
  • Annual Sales, $ 9,891 M
  • Annual Income, $ 1,293 M
  • EBIT $ 2,420 M
  • EBITDA $ 3,493 M
  • 60-Month Beta 0.19
  • Price/Sales 2.83
  • Price/Cash Flow 8.37
  • Price/Book 1.50

Options Overview Details

View History
  • Implied Volatility 30.94% (-1.25%)
  • Historical Volatility 35.44%
  • IV Percentile 9%
  • IV Rank 14.54%
  • IV High 50.85% on 10/16/25
  • IV Low 27.55% on 01/07/26
  • Expected Move (DTE 4) 4.93 (2.54%)
  • Put/Call Vol Ratio 0.35
  • Today's Volume 1,115
  • Volume Avg (30-Day) 1,763
  • Put/Call OI Ratio 0.81
  • Today's Open Interest 54,215
  • Open Int (30-Day) 53,533
  • Expected Range 188.83 to 198.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 35 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $3.36
  • Number of Estimates 21
  • High Estimate $4.40
  • Low Estimate $2.33
  • Prior Year $5.47
  • Growth Rate Est. (year over year) -38.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
179.15 +8.16%
on 04/27/26
205.97 -5.93%
on 05/13/26
+3.69 (+1.94%)
since 04/22/26
3-Month
168.64 +14.90%
on 04/06/26
205.97 -5.93%
on 05/13/26
+1.73 (+0.90%)
since 02/20/26
52-Week
121.05 +60.07%
on 07/21/25
205.97 -5.93%
on 05/13/26
+67.46 (+53.41%)
since 05/22/25

Most Recent Stories

More News
MarketBeat Week in Review – 05/18 - 05/22

Stocks were up sharply to end the week as NVIDIA’s forward guidance showed tangible demand to support AI infrastructure and overshadowed mixed retail reports

NVDA : 215.33 (-1.90%)
DE : 529.15 (-0.41%)
META : 610.26 (+0.47%)
AAPL : 308.82 (+1.26%)
ARHS : 6.32 (-1.10%)
AAOI : 181.49 (+2.65%)
EVTL : 2.62 (+0.38%)
HIVE : 4.07 (+5.71%)
DDS : 561.80 (+1.80%)
TSLA : 426.01 (+1.95%)
SPCX : 21.98 (+0.16%)
MRAM : 33.68 (+3.79%)
Biogen Inc. (BIIB) Securities Fraud Investigation - Levi & Korsinsky

Biogen shares dropped approximately 6.4% in a single session after Phase 2 CELIA trial data for diranersen missed its primary endpoint -- wiping out billions in market value.

BIIB : 193.76 (+2.26%)
Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish

Biogen’s Alzheimer’s drug candidate showed promising tau-targeting results despite missing a primary endpoint, reinforcing long-term optimism for BIIB stock

APLS : 41.03 (-0.07%)
BIIB : 193.76 (+2.26%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

NEW YORK , May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact...

BIIB : 193.76 (+2.26%)
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints  Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue...

DNLI : 18.64 (-3.42%)
BIIB : 193.76 (+2.26%)
Are Wall Street Analysts Bullish on Biogen Stock?

Biogen has rallied the broader market over the past year, and analysts remain moderately optimistic about the stock’s prospects.

XLV : 149.89 (+1.17%)
$SPX : 7,473.47 (+0.37%)
BIIB : 193.76 (+2.26%)
BIIB Investor Alert: Levi & Korsinsky Investigates Biogen Inc. (BIIB) for Potential Securities Fraud

Biogen revealed Phase 2 CELIA trial data that sent BIIB shares down approximately 6.4% in a single session.

BIIB : 193.76 (+2.26%)
BIIB ALERT: Levi & Korsinsky Investigates Biogen Inc. for Possible Securities Fraud Violations

New York, New York--(Newsfile Corp. - May 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Biogen Inc. ("Biogen Inc.") (NASDAQ:BIIB) concerning potential violations...

BIIB : 193.76 (+2.26%)
BIIB SHAREHOLDER INVESTIGATION: SueWallSt Investigates Biogen Inc. for Possible Securities Law Violations

Biogen Phase 2 CELIA trial data sent shares down 6.4% after it was revealed that topline data missed its primary endpoint.

BIIB : 193.76 (+2.26%)
Biogen Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Biogen Inc. (BIIB)

Biogen shares dropped 6.4% after Phase 2 CELIA trial data revealed information absent from the Company's filings.

BIIB : 193.76 (+2.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 200.42
2nd Resistance Point 197.58
1st Resistance Point 195.67
Last Price 193.76
1st Support Level 190.93
2nd Support Level 188.09
3rd Support Level 186.18

See More

52-Week High 205.97
Last Price 193.76
Fibonacci 61.8% 173.53
Fibonacci 50% 163.51
Fibonacci 38.2% 153.49
52-Week Low 121.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.